Lactate Dehydrogenase Therapy - LDH Explained
Lactate dehydrogenase therapy refers to therapeutic approaches targeting the enzyme lactate dehydrogenase (LDH) to treat metabolic disorders and cancer.
Things worth knowing about "Lactate dehydrogenase therapy"
Lactate dehydrogenase therapy refers to therapeutic approaches targeting the enzyme lactate dehydrogenase (LDH) to treat metabolic disorders and cancer.
What is Lactate Dehydrogenase Therapy?
Lactate dehydrogenase therapy (LDH therapy) is a field of medical research and clinical application focused on the targeted modulation of the enzyme lactate dehydrogenase (LDH). LDH is a key enzyme in cellular energy metabolism, catalyzing the interconversion of pyruvate and lactate. Therapeutic strategies targeting LDH are gaining increasing importance, particularly in oncology and metabolic disease management.
Biological Function of Lactate Dehydrogenase
LDH is a ubiquitous enzyme found in virtually all body cells. It plays a central role in anaerobic glucose metabolism (glycolysis) and is responsible for maintaining energy supply under low-oxygen conditions. The enzyme exists in five isoforms (LDH-1 to LDH-5), predominating in different tissues:
- LDH-1 and LDH-2: Mainly in cardiac muscle and red blood cells
- LDH-3: Primarily in lung and lymphoid tissue
- LDH-4 and LDH-5: Primarily in liver and skeletal muscle
Elevated LDH levels in the blood may indicate tissue damage, myocardial infarction, liver disease, or malignant conditions.
Therapeutic Approach: Why LDH as a Target?
Tumor cells preferentially use anaerobic metabolic pathways – a phenomenon known as the Warburg effect – and are therefore particularly dependent on LDH activity. Inhibiting LDH, especially the isoform LDH-A (LDHA), represents a promising approach in cancer therapy. By blocking this enzyme, the energy supply to tumor cells is intended to be disrupted and their growth inhibited.
Mechanism of Action of LDH Inhibition
LDH inhibitors intervene specifically in the metabolism of tumor cells:
- Inhibition of the conversion of pyruvate to lactate in tumor cells
- Accumulation of pyruvate, which is redirected into mitochondrial oxidative metabolism
- Increased oxidative stress in tumor cells
- Induction of apoptosis (programmed cell death) in malignant cells
- Reduction of lactate secretion, which contributes to immunosuppression in the tumor microenvironment
Clinical Areas of Application
Oncology
In cancer medicine, LDH therapy is being investigated as a potential complementary treatment strategy. Elevated LDH blood levels are considered a negative prognostic marker in various cancers, including malignant melanoma, lymphomas, and solid tumors. Substances such as gossypol, oxamate, and newer synthetic LDHA inhibitors are currently in preclinical and early clinical trials.
Metabolic Disorders
In certain metabolic conditions such as lactic acidosis syndrome, modulation of LDH activity may be therapeutically relevant. The goal here is to normalize the lactate-pyruvate balance in the body.
Musculoskeletal Conditions
Since LDH-5 is present in skeletal muscle, LDH activity is being studied as a diagnostic and therapeutically relevant biomarker in conditions involving increased muscle breakdown.
LDH as a Diagnostic Marker
In addition to its therapeutic role, LDH is an important laboratory diagnostic value. Elevated LDH levels may indicate the following conditions:
- Myocardial infarction (heart attack)
- Liver diseases (e.g., hepatitis, liver cirrhosis)
- Hemolytic anemia
- Malignant diseases (e.g., lymphomas, melanoma)
- Kidney disorders
- Pulmonary embolism
The determination of LDH isoforms can help to more precisely identify the origin of cell damage.
Current State of Research
The development of specific LDH inhibitors is a global focus of pharmaceutical research. Numerous studies confirm the importance of LDHA as an oncological target structure. Current research is investigating the combination of LDH inhibitors with conventional chemotherapy or immunotherapy to achieve synergistic effects and overcome tumor cell resistance. Phase I and Phase II clinical trials are underway, but broad clinical approval of specific LDH inhibitors is still pending.
Safety and Side Effects
Since LDH is present in virtually all body cells, systemic inhibition of the enzyme carries potential risks for healthy tissue. Discussed adverse effects include:
- Impairment of energy supply in muscle cells
- Potential effects on cardiac muscle cells
- Alterations in the lactate-pyruvate balance throughout the body
The targeted development of tumor-specific inhibitors that preferentially inhibit LDHA is intended to minimize these risks.
References
- Doherty, J.R. & Cleveland, J.L. (2013). Targeting lactate metabolism for cancer therapeutics. Journal of Clinical Investigation, 123(9), 3685–3692. DOI: 10.1172/JCI69741
- Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.
- Granchi, C. et al. (2014). Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Current Medicinal Chemistry, 21(35), 3972–3987.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryAnal thrombosis
Addison Crisis
Low blood pressure what to do
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Lactate dehydrogenase therapy